during and 4 weeks post RT-TMZ. Kaplan-Meier method was used to calculate overall survival (OS). Multivariable analysis (MVA) assessed for joint effect of covariates on OS and Pearson Correlation Coefficients assessed for association between dexamethasone dose and NLR change. With a median age of 55 (range 18-70), 369 patients were included. Median follow up was 15.1 month (range 1.6-134.6). The OS was 66.1% (95% CI 61.2-70.6) and 31.4 (95% CI 26.8-36.1) at 1 and 2 years, respectively. On univariate analysis, both decrease in NLR post RT-TMZ (HR 0.641, p < 0.0001) and baseline NLR < 7.5 (HR 0.628, p < 0.0001) were associated with longer OS. On MVA decrease in NLR (HR 0.727, 95% CI 0.578-0.915), age (HR 1.025, 95% CI 1.012-1.038), baseline neutrophil (<8) (HR 0.689, 95% CI 0.532-0.891), total TMZ cycles (HR 0.89, were independent predictors of OS. These findings suggest that a decrease in NLR during RT-TMZ, accounting for known prognostic factors, is an independent prognostic factor for survival in GBM.
Introduction
Glioblastoma (GBM), the most common primary brain malignancy in adults [1] , is notorious for it's poor prognosis. The randomized European Organization for Research and Treatment of Cancer (EORTC) and National Cancerstandard treatment for relatively fit patients aged less than 70 [2] . This multimodality regimen resulted in a modest improvement in median survival from 12.1 months with radiotherapy alone to 14.6 months.
Recognized pre-treatment prognostic factors include age, Eastern Cooperative Oncology Group (ECOG) performance status and extent of surgical resection [3] [4] [5] . More recently, molecular characteristics have been identified and demonstrated to provide predictive and prognostic information, including the promoter methylation status of O6-methylguanine-DNA methyltransferase (MGMT) and IDH-1 mutation status [6] . The formal use of these markers in the clinical decision-making process remains undefined and access to these tests can be limited and are not without cost.
With the introduction of Hanahan and Weinberg's 'Hallmarks of Cancer', the impact of the interplay between malignant cells and the host's inflammatory response on outcome has been under investigation [7, 8] . In this context, an elevated neutrophil-lymphocyte ratio (NLR) from peripheral blood samples has been reported to be associated with poorer survival in multiple solid malignancies including esophageal [9] , hepatic [10] , thoracic [11] , prostatic [12] and colorectal [13] cancers. In 2013, Templeton et al. published a systematic review noting 75 studies including over 33,000 patients reporting that NLR above a median cut off of 4, was associated with poorer survival (HR 1.81 95% CI 1.67-1.97; p < 0.001) across multiple tumor sites [14] . In patients with GBM, Bambury et al. found that in patients with newly diagnosed GBM, an elevated NLR > 4 prior to corticosteroid therapy or surgery predicted a poorer outcome [15] and McNamara et al. found that NLR above 4 prior to second surgery predicted shorter survival in patients with recurrent glioblastoma [16] .
The aims of this study were to determine if the baseline and dynamics in hematological parameters, including NLR, can offer further prognostic information for patients treated with RT-TMZ post operatively for newly diagnosed GBM. Such prognostic information obtained from analysis of routinely collected blood results may contribute to the management decisions of physicians and patients.
Methods
This retrospective study describes a cohort of patients treated at a tertiary referral cancer center between January 2004 and December 2011. Following research and ethics approval, an electronic search was performed to identify patients with GBM assessed for postoperative RT-TMZ. Inclusion criteria included adult patients (>18 years old) with a new histologically confirmed diagnosis of GBM who were fit for treatment with focal RT (54-60 Gy in 30 fractions) with concomitant and adjuvant TMZ.
Baseline patient demographics including age, gender, body surface area (BSA) and performance status were gathered. Surgical and nonsurgical treatment information was also collected. Surgical details included the date of surgery and extent of surgical resection stratified using the operative report and postoperative magnetic resonance imaging (MRI) as follows: total resection (100%), subtotal resection (>90 to <100%), partial resection (<90%) or biopsy. Radiotherapy data included total dose and number of fractions with respective dates and volumetric data, including gross tumor volume (GTV = post operative surgical cavity and gross residual disease as seen by enhancement on T1 with gadolinium).
As part of standard institutional practice, each patient receiving concurrent RT-TMZ had complete blood counts obtained at baseline, weekly during radiation and approximately 4 weeks following completion of concurrent RT-TMZ (i.e. week 10). From these complete blood counts results, the NLR was calculated at each time point by dividing the absolute neutrophil count (×10e9/L) by the absolute lymphocyte count (×10e9/L). Dexamethasone doses (mg) at each clinic appointment (baseline, weekly during radiotherapy and 4 weeks following completion of RT-TMZ) were recorded and used to calculate a Time-Weighted mean (TWM) dexamethasone dose (mg). This represents the average dose of dexamethasone received from baseline to 28 days post treatment accounting for each daily dose received and was defined by:
where ω i is the proportion of days each dose was taken from baseline to 28 days post RT and x i dose of dexamethasone.
Statistics
The primary objective of the study was to determine if change in NLR during RT-TMZ could predict overall survival. Secondary objectives included the assessment of other static and dynamic hematological parameters with respect to prognostic value including; platelets, lymphocytes, neutrophil and baseline NLR. It was hypothesized that an increase in dexamethasone exposure could elevate the NLR and therefore assessment for a correlation between Dexamethasone and NLR was also undertaken. It was also considered that magnitude of GTV may correlate with baseline NLR and thus an attempt was made to determine if such a correlation existed.
The primary endpoint was overall survival calculated from date of initial histological diagnosis to date of death. In the context of this retrospective cohort, pseudo-progression was not recognized or reported consistently across all patients during the time period in which this patient cohort was treated, and therefore true progression free survival proved an inconsistent variable and was not reported.
Categorical parameters including gender, ECOG performance status and extent of surgical resection were described using counts and percentages. Medians and ranges summarized continuous variables such as age, hematological parameters, dexamethasone dose, followup duration and overall survival. Linear Mixed model was used for the covariates Neutrophil, Lymphocytes, Platelets, NLR, Platelet to Lymphocyte Ratio (PLR) and dexamethasone dose over time to obtain rates of change over time for each patients. For NLR and PLR, the unit of change is measured per day. As NLR might vary depending on clinical context we did not use a predefined threshold value. Having confirmed that baseline NLR was significantly associated with OS, when analyzed as a continuous variable, binary partition methods were used to calculate a statistically optimized cut-off for baseline NLR analysis.
The Kaplan-Meier product-limit method was used to calculate overall survival. Univariate analysis was performed using the Log rank test and with Cox proportional hazards regression used to assess the joint effect of covariates on OS that were found potential at the Univariate level and/or that are clinically important. All p-values were 2-sided. A criteria of p < 0.05 was used for covariates to remain in the multivariable cox model. Statistical analyses were performed using SAS version 9.4 of the SAS system (SAS Institute Inc, Cary, NC) and R version 3.0.3, the R foundation for statistical computing.
Results

Baseline characteristics
A total of 393 patients met inclusion criteria for this study of which 369 had hematological data available at sufficient study time points allowing for inclusion in full data analysis. The baseline characteristics of the patients included in the full analysis (n = 369) are summarized in Table 1 . The median age of patients at diagnosis was 55 years (range 18-70) and 90% of patients were ECOG PS 0-1. The median body surface area for patients was 1.9 m Table 2 provides a summary of the hematological variables during the study period. Patients were divided into two groups around the median change in NLR of −0.01, which incidentally grouped patients into those with a decline in NLR (n = 206) and those without a decline in NLR (n = 163). The median age for patients were not significantly different between those who had a decline in NLR versus no decline 53 versus 53.4 years (p = 0.58). More males were more likely to have a decline in NLR than females 145/206 males (70.4%) versus 94/163 females (57.7%) p-value = 0.0134, OR = 1.72 with 95% CI (1.12-2.64).
Survival outcome
The median follow up was 15 Patients were further stratified into four groups according to baseline NLR and subsequent change during focal RT-TMZ. Those with a baseline NLR below 7.5 and a subsequent decline in NLR (n = 132) had the best prognosis with a 1-year survival of 77% (95% CI 69-83%) and median OS of 22.7 months (95% CI 16.8-28.8 months). A baseline NLR < 7.5 without a subsequent decline in NLR (n = 65) had a 1-year survival rate of 69% (95% CI 56-79%) and median OS of 15.3 months (95% CI 12.9-19.6 months). For patients with a baseline NLR > 7.5, those with a decline (n = 74) had 1 year survival of 65% (95% CI 53-75%) and median OS of 15.0 months (95% CI 12.4-16.9 months) whereas those who did not have a decline (n = 98) had 1 year survival of 52% (95% CI 42-61%) and median OS of 12.9 months (7.4-14.6 months). Figure 1b depicts the OS for these groups.
Univariate analysis results
When previously identified prognostic factors were evaluated on univariate analysis (as summarized in Table 3 ), age (HR 1.034, p < 0.0001) and ECOG PS ≤ 1 (HR 0.449, p < 0.0001) were associated with OS while extent of surgery was not (HR 1.229 p = 0.2285). Hematological variables associated with longer survival included baseline NLR below 7.5 (HR 0.628, p < 0.0001), baseline neutrophil count of less than 8 × 10 9 /L (HR = 0.70, p = 0.0015), declining platelet count (HR 0.716, p = 0.0085) and declining NLR (HR 0.641, p < 0.0001) during RT-TMZ. Baseline platelet count and change in neutrophils were not statistically significant. In terms of treatment variables, the total 
Tests for collinearity
A test for collinearity between dexamethasone dose and NLR showed a weak correlation between dexamethasone dose and NLR (mean ρ = 0.237). Figure 2 shows no 
Discussion
This study validates prior findings that an elevated baseline NLR in the context of GBM predicts a poorer overall survival although the 'baseline' NLR threshold value in our study was higher than the previously reported value of 4 such that in our study a baseline NLR < 7.5 resulted in HR 0.628 of death (p < 0.0001) [15, 16] . This is likely due to our baseline NLR values being in the postoperative setting in patients largely exposed to corticosteroids compared with the prior study in which the baseline NLR was measured prior to any corticosteroids or surgery. In addition to baseline NLR, this study suggests that dynamic changes of NLR during focal radiotherapy and concomitant TMZ may yield stronger prognostic information. Patients with a decline in NLR during treatment had better survival than those without a decline in NLR with 1-year OS of 72.9% (95% CI 66.3-78.4) compared with Lymphopaenia with a decrease of peripheral CD4 + T Cells, NK, and CD8 + CD56 + effector cells but not CD8 + was reported [17] . In our study on univariate analysis, both a lower baseline neutrophil count (p = 0.01) and lymphocyte count (p = 0.004) was associated with increased overall survival. During treatment, change in neutrophil count was not predictive of overall survival (HR 4.61, p = 0.72) however, on univariate analysis, an increase in lymphocyte count was related to longer survival (p = 0.002). Change in lymphocyte count was no longer associated with survival on multivariable analysis. Systemic changes in blood counts may reflect events in the tumor microenvironment. Tumor infiltration by T cells has been reported in glioblastoma and suggested to correlate with integrity of the blood brain barrier [18] . Furthermore, in 44 patients a correlation between effector T cells (cytotoxic and helper) but not regulatory T cells was seen [18] . Han et al. reported an association between an elevated preoperative NLR with increased neutrophil infiltration and low CD3 + T-cell infiltration into glioblastoma [19] . A recent in-vitro study has suggested neutrophil infiltration not only correlates with tumor grade but also development of resistance to anti-VEGF therapy [20] . Tumor associated neutrophilia has been associated with poorer outcomes in advanced malignancy [21, 22] and shorter survival in following recurrent disease [23] . Tumor production of factors such as Granulocyte-Macrophage Colony Stimulating Factors and an Interleukin-3-like molecule may potentially drive such a process [24] . In the context of malignant glioma, Fossati et al. reported the extent of neutrophilia and tumor infiltration by neutrophils correlated with tumor grade and hypothesized that this was potentially driven by tumor-derived factors [25] . Neutrophils may have different phenotypes, both pro-tumor and anti-tumor [26] and have been linked with tumor progression [27] , angiogenesis [28] and in the promotion of metastatic colony development [29] . Interestingly IFN-γ stimulated neutrophils have been demonstrated to express Programmed death-ligand 1 (PD-L1) and suppress lymphocyte proliferation [30] . Now that we are equipped with drugs that target such ligands, further exploration is warranted to determine if the use of NLR as a simple screening tool or response marker has merit.
Lymphopaenia in response to treatment has been linked to worse outcomes [31] . Grossman et al. reported treatment-induced lymphopaenia in solid tumors of which 96 patients had malignant glioma. A post treatment lymphopaenia (<500 cells/mm 3 ) was associated with a shorter survival (16 vs. 18 months). Future work correlating peripheral blood parameters and tumor infiltrates may provide insight into the interplay between the tumor microenvironment and systemic immune system. Of the known prognostic factors, age and ECOG performance were associated with OS in this cohort, but extent of surgery was not found to be statistically significant. This may be a reflection of the fact that over 65% had partial resections as per our definition and this variable was not normally distributed. On multivariable analysis, the dynamic measurement of NLR change remained significant (p = 0.0031) while the baseline NLR was no longer statistically significant (p = 0.9127). Comparing patients with or without a decline in NLR, age was not statistically significant different (p value = 0.5788); however it was noted that patients with a declining NLR during treatment were more likely to be male with 60.67% of males vs. 47.33% of females having a decline in NLR (p = 0.0134, OR 1.72, 95% CI 1.12-2.64). We questioned whether this reflected a higher dose of TMZ received per cycle as result of higher body surface area. However, prior population pharmacokinetic studies have reported that higher BSA is associated with increased clearance of temozolomide and female gender with lower clearance [32] . Therefore, the relationships between BSA and NLR as well as BSA and survival were explored. On multivariable analysis, an increase in BSA was associated with shorter survival (HR 1.78, p = 0.0382), and BSA did not correlate with change in NLR (ρ = −0.023, p = 0.6608).
It was also hypothesized that NLR would be associated with dexamethasone use. The mean baseline dexamethasone dose (8 mg) being greater than the time weighted mean dose (4.9 mg) reflects that patients generally tapered off steroids during their course of radiotherapy and temozolomide. Dexamethasone is known to produce a neutrophilia with suppression of neutrophil apoptosis [33, 34] . Conversely, exposure of T cells to dexamethasone has been shown to promote apoptosis [35] . Gustafason et al. reported an intensification of tumor-associated lymphopaenia, predominantly T cells with dexamethasone [36] . However, the current data suggested the correlation between dexamethasone dose and NLR was weak (mean ρ = 0.22).
Limitations of this study include that it is a single center retrospective cohort study. This data reflects a cohort of patients treated prior to standard assessment of MGMT promoter methylation status or IDH-1 mutation testing. Despite efforts to retrieve tissue for testing, IDH-1 mutation status testing could be completed in only 23.9% of patients of which only 4.3% harbored the IDH1 mutation. This was largely due to referrals from a wide number of centers to this tertiary level institution following tissue diagnosis of glioblastoma. Additionally, this patient population received treatment in the era prior to the recognition of pseudo-progression and therefore patients received 'salvage' treatment upon radiological progression, hindering meaningful evaluation of true progression free survival in our cohort. An assessment of change of NLR could be undertaken prospectively in a contemporary cohort to validate our findings and to determine whether change in NLR may help identify tumor progression from pseudo-progression in the future.
In this study cohort of 369 patients with GBM a reduction in NLR during RT-TMZ was prognostic for longer survival, independent of other known prognostic factors including age, ECOG performance status and dexamethasone use. Our study also validates that an elevated baseline NLR is associated with a poorer prognosis. When these hematological factors are combined, patients with low baseline NLR and further reduction in NLR during treatment, with a median OS for this group 22.7 months (95% CI 16.8-28.8 months), had significantly longer survival. Particularly with growing interest in the effect of immune response in the treatment of gliomas, this readily accessible prognostic marker based on conventional blood tests may serve as a useful tool for patient selection for clinical trials and interventions.
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